Amoxicillin and Metronidazole During Periodontal Treatment
- Conditions
- Chronic Periodontitis
- Interventions
- Procedure: Scaling and root planingDrug: Placebos active phaseDrug: Placebos healing phase
- Registration Number
- NCT02954393
- Lead Sponsor
- Belén Retamal-Valdes
- Brief Summary
The aim of this multicenter randomized clinical trial is to compare the clinical, microbiological and immunological effects of the adjunctive use of systemic metronidazole plus amoxicillin administered in different phases of the treatment of generalized chronic periodontitis.
- Detailed Description
The combination of systemic metronidazole (MTZ) and amoxicillin (AMX) to scaling and root planing (SRP) has shown to be a promising periodontal treatment. However, some essential issues associated with the use of these antibiotics remain to be established. Although these agents are often prescribed after the healing phase of the SRP procedure, there is biological plausibility to support its use in conjunction with the mechanical treatment. However, to date, no placebo controlled randomized clinical trial (RCT) has directly compared these two protocols. Therefore, the aim of this multicentric RCT is to compare the clinical, microbiological and immunological effects of adjunctive systemic MTZ+AMX administered in different phases of the treatment of generalized chronic periodontitis (GChP). 180 subjects with GChP will be randomly assigned into three groups (n=60/group) that will receive SRP-only (control group) or in combination with 400 mg MTZ+500 mg AMX beginning at the first SRP session (group test 1) or after 3 months of its completion (group test 2). All volunteers will receive clinical and microbiological evaluation at baseline, 3, 6 and 12 months, and immunological assessment (levels of 20 chemokines) at baseline and 12 months post-therapy. Nine subgingival biofilm samples will be collected by subject and analyzed for counts and proportions of 40 bacterial species by checkerboard DNA-DNA hybridization. Differences in clinical, microbiological and immunological parameters among groups and over time will be evaluated using the ANOVA, ANCOVA, Chi-square and Tukey tests. Microbiological analyzes will be performed using adjustments for multiple comparisons. Statistical significance will be set at 5%.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 180
- ≥35 years of age;
- at least 15 teeth (excluding third molars and teeth with advanced decay indicated for extraction);
- a minimum of 6 teeth with at least one site each with probing depth (PD) and clinical attachment level (CAL) ≥5 mm;
- at least 30% of the sites with PD and CAL ≥4 mm and bleeding on probing (BOP).
- pregnancy;
- breastfeeding;
- current smoking and former smoking within the past 5 years;
- systemic diseases that could affect the progression of periodontitis (e.g. diabetes, immunological disorders, osteoporosis);
- scaling and root planing an in the previous 6 months;
- antibiotic therapy in the previous 6 months;
- long-term intake of anti-inflammatory medications;
- need for antibiotic pre-medication for routine dental therapy;
- use of orthodontic appliances;
- extensive dental prosthetic rehabilitation;
- allergy to metronidazole and/or amoxicillin.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Healing phase Amoxicillin healing phase Scaling and root planing + Placebos active phase thrice a day (TID) for 14 days and Metronidazole healing phase (400 mg/TID) + Amoxicillin healing phase (500 mg/TID) for 14 days. Control Scaling and root planing Scaling and root planing + Placebos active phase thrice a day (TID) for 14 days and Placebos healing phase TID for 14 days. Control Placebos active phase Scaling and root planing + Placebos active phase thrice a day (TID) for 14 days and Placebos healing phase TID for 14 days. Control Placebos healing phase Scaling and root planing + Placebos active phase thrice a day (TID) for 14 days and Placebos healing phase TID for 14 days. Active phase Scaling and root planing Scaling and root planing + Metronidazole active phase (400 mg/thrice a day,TID) + Amoxicillin active phase (500 mg/ TID) for 14 days and Placebos healing phase TID for 14 days. Active phase Metronidazole active phase Scaling and root planing + Metronidazole active phase (400 mg/thrice a day,TID) + Amoxicillin active phase (500 mg/ TID) for 14 days and Placebos healing phase TID for 14 days. Active phase Amoxicillin active phase Scaling and root planing + Metronidazole active phase (400 mg/thrice a day,TID) + Amoxicillin active phase (500 mg/ TID) for 14 days and Placebos healing phase TID for 14 days. Active phase Placebos healing phase Scaling and root planing + Metronidazole active phase (400 mg/thrice a day,TID) + Amoxicillin active phase (500 mg/ TID) for 14 days and Placebos healing phase TID for 14 days. Healing phase Scaling and root planing Scaling and root planing + Placebos active phase thrice a day (TID) for 14 days and Metronidazole healing phase (400 mg/TID) + Amoxicillin healing phase (500 mg/TID) for 14 days. Healing phase Metronidazole healing phase Scaling and root planing + Placebos active phase thrice a day (TID) for 14 days and Metronidazole healing phase (400 mg/TID) + Amoxicillin healing phase (500 mg/TID) for 14 days. Healing phase Placebos active phase Scaling and root planing + Placebos active phase thrice a day (TID) for 14 days and Metronidazole healing phase (400 mg/TID) + Amoxicillin healing phase (500 mg/TID) for 14 days.
- Primary Outcome Measures
Name Time Method Percentage of subjects reaching ≤ 4 periodontal sites with probing depth (PD) ≥ 5 mm at 12 months 12 months
- Secondary Outcome Measures
Name Time Method Number of sites with PD ≥ 5 mm. Baseline, 3, 6 and 12 months. Number of sites with PD ≥ 6 mm. Baseline, 3, 6 and 12 months. Reduction in the number of sites with PD ≥ 5 mm. Baseline, 3, 6 and 12 months. Reduction in the number of sites with PD ≥ 6 mm. Baseline, 3, 6 and 12 months. Mean CAL changes in sites with initial CAL ≥ 7 mm. Baseline - 12 months. Full-mouth clinical attachment level. Baseline, 3, 6 and 12 months. Percentage of sites with plaque accumulation Baseline, 3, 6 and 12 months. Percentage of sites with marginal bleeding. Baseline, 3, 6 and 12 months. Occurrence of headache obtained through a questionnaire of adverse effects. 14 days after taking antibiotic. Proportions of periodontal pathogenic bacterial species. Baseline, 3, 6 and 12 months. Number of sites with PD ≥ 7 mm. Baseline, 3, 6 and 12 months. Reduction in the number of sites with PD ≥ 7 mm. Baseline, 3, 6 and 12 months. Mean PD changes in sites with initial PD between 4-6 mm Baseline - 12 months. Mean PD changes in sites with initial PD ≥ 7 mm. Baseline - 12 months. Mean CAL changes in sites with initial CAL between 4-6 mm Baseline - 12 months. Full-mouth PD. Baseline, 3, 6 and 12 months. Percentage of sites with bleeding on probing. Baseline, 3, 6 and 12 months. Occurrence of vomiting obtained through a questionnaire of adverse effects. 14 days after taking antibiotic. Occurrence of diarrhea obtained through a questionnaire of adverse effects. 14 days after taking antibiotic. Occurrence of metallic taste obtained through a questionnaire of adverse effects. 14 days after taking antibiotic. Occurrence of nausea obtained through a questionnaire of adverse effects. 14 days after taking antibiotic. Occurrence of irritability obtained through a questionnaire of adverse effects. 14 days after taking antibiotic. Counts of chemokines in the crevicular gingival fluid. Baseline and 12 months. Counts of periodontal pathogenic bacterial species. Baseline, 3, 6 and 12 months.
Trial Locations
- Locations (2)
University of São Paulo
🇧🇷São Paulo, Brazil
University of Guarulhos
🇧🇷Guarulhos, São Paulo, Brazil